Kura Oncology Reports 67% Response Rate for Darlifarnib Combo in Pancreatic Cancer at ASCO

Why It Matters

Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, with five‑year survival rates below 10%. The 67% ORR reported by Kura suggests that targeting the farnesylation pathway can meaningfully augment KRAS inhibition, offering a new therapeutic avenue where few exist. Moreover, the data demonstrate activity in patients previously exposed to KRAS inhibitors, addressing a critical resistance gap that has limited the durability of existing monotherapies. If Kura’s platform can consistently deliver high response rates across tumor types, it could shift the industry focus from single‑agent KRAS inhibitors to combination regimens that pre‑empt or overcome adaptive resistance. This would have ripple effects on drug development pipelines, investment strategies, and clinical practice guidelines for KRAS‑mutant malignancies.

Key Takeaways

• Kura Oncology reported a 67% confirmed objective response rate for darlifarnib + adagrasib in KRAS G12C‑mutated pancreatic cancer (26 evaluable patients).
• Tumor shrinkage was observed in 77% of patients overall and 94% of KRAS‑inhibitor‑naïve patients.
• 40% of the 30 FIT‑001 participants had prior KRAS inhibitor exposure, yet the combination remained active.
• Next trial arm will pair darlifarnib with daraxonrasib, targeting Phase 1a entry in early 2027.
• Kura’s adaptive platform aims to add new combinations without separate IND filings, pending pre‑specified response thresholds.

Pulse Analysis

Kura Oncology’s early data could be a watershed for KRAS‑targeted therapy, not because the numbers are unprecedented—monotherapy sotorasib achieved a 36% ORR in NSCLC—but because the combination appears to overcome a key limitation: resistance after prior KRAS inhibition. The farnesyl transferase inhibitor’s ability to block RHEB farnesylation and sustain mTORC1 suppression addresses a well‑documented adaptive pathway that tumors exploit when KRAS signaling is shut down. By hitting both the KRAS node and its downstream escape route, Kura may be delivering a more durable blockade.

The strategic choice to anchor the platform on pancreatic cancer is bold. PDAC has historically been a recruitment nightmare, and any delay can cede ground to rivals like Mirati or Amgen, which are also pursuing KRAS‑based combos. Kura’s adaptive trial design—allowing new arms to open without separate INDs—could accelerate data generation, but only if enrollment targets are met. Investors will be scrutinizing the upcoming daraxonrasib arm for both speed and depth of response.

Looking ahead, the real test will be whether the high ORR translates into meaningful survival benefits and manageable safety. If Kura can demonstrate durable responses with an acceptable toxicity profile, it may set a new standard for KRAS‑mutant cancers, prompting larger pharmaceutical players to adopt similar combination strategies. The next 12‑18 months will be critical in determining whether this early promise evolves into a market‑changing therapy or remains an intriguing pre‑clinical concept.